Nanollose Limited
Nanollose Limited
Your view on NC6.AX
Overview
What the company does, where it operates, and who runs it.
About Nanollose Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Andrew Moullin
- Headquarters
- 145 Stirling Highway, Nedlands, WA, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Andrew Moullin
- Headquarters
- 145 Stirling Highway, Nedlands, WA, AU
Nanollose Limited is an Australian biomaterials enterprise dedicated to the research, development, and commercialization of microbial nanocellulose technology.
Its product line features Nullarbor Fibre, an innovative lyocell fibre produced without relying on trees, and Jelli Grow, an eco-friendly substitute for seed germination and cultivating plants. These materials find applications across various sectors, including textiles, nonwoven fabrics, and other industries.
Established in 2014, the company's headquarters are situated in Nedlands, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Nanollose Limited. Starting points for Nanollose Limited: EPS -AUD 0.0060, beta 0.68 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Nanollose Limited. Nanollose Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Nanollose Limited. Trailing twelve-month EPS for Nanollose Limited stands at -AUD 0.0060. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Nanollose Limited. Nanollose Limited has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| AVE.AXAvecho Biotechnology Limited | Healthcare | Biotechnology | — | ||
| BTC.AXBTC Health Limited | Healthcare | Biotechnology | — | ||
| FRE.AXFirebrick Pharma Limited | Healthcare | Drug Manufacturers - General | — | ||
| IMC.AXImmuron Limited | Healthcare | Biotechnology | — | ||
| IME.AXImExHS Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| NTI.AXNeurotech International Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PSYBFPsyBio Therapeutics Corp. | Healthcare | OTC | $1,275 | ||
| PTCHFPureTech Health plc | Healthcare | OTC | $410.4M | ||
| PTCTPTC Therapeutics, Inc. | Healthcare | NASDAQ | $5.0B | ||
| PTGXProtagonist Therapeutics, Inc. | Healthcare | NASDAQ | $8.3B | ||
| PTHSPelthos Therapeutics Inc. | Healthcare | AMEX | $27.9M | ||
| PTIXProtagenic Therapeutics, Inc. | Healthcare | NASDAQ | $470,654 | ||
| PTNPalatin Technologies, Inc. | Healthcare | NASDAQ | $9.2M | ||
| PTX.AXPrescient Therapeutics Limited | Healthcare | ASX | — | ||
| PULMPulmatrix, Inc. | Healthcare | NASDAQ | $4.9M | ||
| PVCTProvectus Biopharmaceuticals, Inc. | Healthcare | OTC | $18.7M | ||
| PVLAPalvella Therapeutics, Inc. | Healthcare | NASDAQ | $2.1B | ||
| PXMDPaxMedica, Inc. Common Stock | Healthcare | OTC | $37,879 | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Nanollose Limited.